BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 3802110)

  • 1. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.
    Cassileth PA; Begg CB; Silber R; Spiers A; Burkart PT; Scharfman W; Knospe WH; Bennett JM; Mazza JJ; Oken MM
    Cancer Treat Rep; 1987 Feb; 71(2):137-40. PubMed ID: 3802110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute leukemia with amsacrine and high-dose cytarabine.
    Arlin ZA; Gaddipati J; Ahmed T; Mittelman A; Friedland M; Rieber E
    Cancer Treat Rep; 1985 Sep; 69(9):1001-2. PubMed ID: 3839713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
    Deliliers GL; Annaloro C; Oriani A; Della Volpe A; Boschetti C; Cortelezzi A; Maiolo AT
    Ann Ital Med Int; 1998; 13(3):146-51. PubMed ID: 9859570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia.
    Tauro S; Shankaranarayana P; Nitu-Whalley IC; Duncan N; Begum G; Craig JI; Marcus RE; Craddock CF; Mahendra P
    Bone Marrow Transplant; 2003 Aug; 32(3):273-8. PubMed ID: 12858198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
    Hewlett JS; Chen T; Balcerzak SP; Gutterman JU; Costanzi JJ; Amare M
    Arch Intern Med; 1985 Jun; 145(6):1006-12. PubMed ID: 3890786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
    Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
    Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.
    Isnard F; Guiguet M; Laporte JP; Zunic P; Elloumi M; Chéron N; Deloux J; Van Den Akker J; Lesage S; Fouillard L; Aoudjhane M; Lopez M; Douay L; Gorin NC; Najman A
    Bone Marrow Transplant; 2001 May; 27(10):1045-52. PubMed ID: 11438819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute non-lymphocytic leukemia in Saitama Cancer Center.
    Sampi K; Sakurai M; Kaneko Y; Hattori M
    Anticancer Res; 1985; 5(3):293-6. PubMed ID: 4015043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.